According to Zydus Lifesciences's latest financial reports the company has NZ$0.62 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-03-31 | NZ$0.23 B | -64.41% |
2022-03-31 | NZ$0.65 B | 200.37% |
2021-03-31 | NZ$0.21 B | -19.25% |
2020-03-31 | NZ$0.27 B | 42.49% |
2019-03-31 | NZ$0.19 B | -49.87% |
2018-03-31 | NZ$0.38 B | 7.48% |
2017-03-31 | NZ$0.35 B | 90.28% |
2016-03-31 | NZ$0.18 B | 16.19% |
2015-03-31 | NZ$0.15 B | 35.34% |
2014-03-31 | NZ$0.11 B | -20.66% |
2013-03-31 | NZ$0.14 B | 32.42% |
2012-03-31 | NZ$0.11 B | 29.57% |
2011-03-31 | NZ$86.83 M | 9.71% |
2010-03-31 | NZ$79.14 M | -10.54% |
2009-03-31 | NZ$88.47 M | 199.15% |
2008-03-31 | NZ$29.57 M | -7.71% |
2007-03-31 | NZ$32.04 M | 100% |
2006-03-31 | NZ$16.02 M | -18.65% |
2005-03-31 | NZ$19.69 M | 28.74% |
2004-03-31 | NZ$15.29 M |